Confo Therapeutics expands Board with appointment of Rob Scott as Independent Director

News
- 10/06/2020

Ghent, Belgium: 10 June 2020 – Confo Therapeutics today announced the addition of a new member to its Board of Directors with the appointment of Rob Scott, MD, as an Independent Director. Dr Scott’s career spans 30 years of drug discovery and development leadership in the global pharmaceutical and biotechnology industries, including his last position as Chief Medical Officer, Head of Development at AbbVie. Dr Scott’s successful track record of bringing highly innovative new medicines to patients will be of increasing value as Confo focuses on moving its drug development programs toward the clinic.

More info on Confo Therapeutics’ website.